Sanofi (NASDAQ:SNY) Receives Consensus Rating of “Moderate Buy” from Brokerages

Sanofi (NASDAQ:SNY) has been given a consensus rating of “Moderate Buy” by the four ratings firms that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $57.50.

A number of equities analysts have commented on SNY shares. Citigroup raised Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 7th.

Sanofi Stock Up 0.9 %

Shares of SNY opened at $48.72 on Thursday. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The stock has a 50 day simple moving average of $53.17 and a two-hundred day simple moving average of $52.15. The firm has a market cap of $123.64 billion, a P/E ratio of 24.86, a P/E/G ratio of 1.22 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. The firm had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business’s quarterly revenue was up 12.3% on a year-over-year basis. During the same period in the previous year, the business posted $2.55 EPS. On average, analysts forecast that Sanofi will post 4.29 earnings per share for the current fiscal year.

Institutional Trading of Sanofi

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. B. Riley Wealth Advisors Inc. lifted its position in shares of Sanofi by 32.4% in the 1st quarter. B. Riley Wealth Advisors Inc. now owns 20,925 shares of the company’s stock worth $1,122,000 after purchasing an additional 5,117 shares during the period. Tidal Investments LLC purchased a new position in shares of Sanofi during the 1st quarter worth approximately $228,000. Atria Investments Inc raised its position in shares of Sanofi by 31.1% in the 1st quarter. Atria Investments Inc now owns 98,878 shares of the company’s stock worth $4,805,000 after acquiring an additional 23,463 shares in the last quarter. Redwood Grove Capital LLC lifted its stake in shares of Sanofi by 9.1% in the 1st quarter. Redwood Grove Capital LLC now owns 261,154 shares of the company’s stock valued at $12,692,000 after purchasing an additional 21,710 shares during the period. Finally, Cetera Investment Advisers boosted its position in shares of Sanofi by 245.4% during the first quarter. Cetera Investment Advisers now owns 178,349 shares of the company’s stock valued at $8,668,000 after purchasing an additional 126,712 shares in the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.